각막 반흔 시장은 코르티코스테로이드 국소 투여와 마이토마이신 C 국소 투여가 크게 기여하고 있으며, 2034년까지 새로운 신흥 치료제의 도입은 각막 반흔 치료제 시장에 극적인 변화를 가져오는 중요한 돌파구가 될 것입니다. 조사 대상 국가(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 각막 반흔 치료용 신흥 치료제 매출은 2020-2034년 기간 동안 3.60%의 CAGR로 성장하여 2034년까지 총 57억 달러의 시장 규모를 형성할 것으로 예상됩니다.
각막 반흔은 각막백반증 또는 각막혼탁이라고도 하며, 각막의 투명성과 시기능에 영향을 미치기 때문에 중요한 관심사입니다. 각막의 고도로 조직화된 투명한 구조는 빛을 망막으로 전달하는 기능에 매우 중요하며, 이 구조가 파괴되면 반흔 조직이 형성되어 시력을 손상시킬 수 있습니다.
각막의 반흔 형성은 종종 섬유화된 세포 반응의 결과이며, 이 세포 반응은 조직의 치유를 목표로 하지만 투명성을 회복할 수 없습니다. 각막 질환이나 부상으로 인한 반흔은 영구적인 시력 저하로 이어질 수 있기 때문에 큰 우려 사항입니다. 각막의 반흔 조직 형성의 영향은 시력에 직접적인 영향을 미치기 때문에 다른 조직에 비해 특히 심각합니다.
이 보고서는 주요 7개국의 각막 반흔 시장을 조사하여 시장 현황과 함께 질환 개요 및 치료법, 환자 동향, 지역별 동향, 미충족 수요 및 향후 전망 등을 제공합니다.
The Corneal Scarring market is hugely contributed using topical corticosteroids and local application of mitomycin C. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Corneal Scarring therapeutics market. The sales of the emerging therapies for the treatment Corneal Scarring in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $5.7 Billion by 2034.
"Depending on the depth of the scar, different surgical procedures are recommended to remove the scar. In the outer layers of the cornea, the scar may be able to be peeled or scraped away. A scar in the middle layer may be able to be removed in a laser procedure known as PTK (Photo Therapeutic Keratectomy). Corneal transplants, either full or partial, can also be performed to remove the section of the cornea containing the scar."
Corneal Scarring, also known as corneal leukoma or corneal opacity, is a significant concern due to its impact on the transparency and visual function of the cornea. The cornea's highly organized and transparent structure is crucial for its function in transmitting light onto the retina, and any disruption to this architecture can lead to scar tissue formation, impairing vision.
Scarring in the cornea is often the result of fibrotic cellular responses, which, while aiming to heal the tissue, fail to restore its transparency. This is a major concern in corneal diseases and injuries, as scarring can lead to permanent vision loss. The impact of scar tissue formation in the cornea is particularly significant compared to other tissue types, as it directly affects vision.
Mellalta's Corneal Scarring Report- Market Summary
Market Size 2034: $5.7 billion
CAGR%: 3.60%
Key Market Players: Claris Biotherapeutics
Forecast Period: 2020-2034
Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.
Current SOC: Topical corticosteroids; Local application of mitomycin C;
Future SOC: Hepatocyte Growth Factor (HGF)
Key Unmet Need: Standardized Treatment Guidelines; Lack of Approved Pharmaceutical Interventions; Demand for Safer and More Efficacious Treatment Options
Key Insights: Given their affordability and accessibility, current SOC therapies remain viable options for a significant portion of patients.
Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options
Mellalta's Corneal Scarring Report - Epidemiology
The total prevalent cases of Corneal Scarring in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). This increase translates to a CAGR of approximately 0.6% over the 15-year forecast period, underscoring a steady escalation in the incidence of Corneal Scarring. As per estimates, the United States will present with the highest prevalence of Corneal Scarring cases in 2034. Among the EU5, Germany had the highest Corneal Scarring cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.
Mellalta's Corneal Scarring Report - Current Market Size & Forecast Trends
The Corneal Scarring therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 5.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.
The current standard of care is limited to therapies such as prednisone acetate ophthalmic suspension, a topical corticosteroid, which is well-established for minimizing corneal scarring, leveraging its anti-inflammatory and antifibrotic properties. Corticosteroids have shown efficacy in reducing TGFb expression, which is considered a key mechanism for antifibrotic therapy in the cornea. MMC, on the other hand, is a potent mitotic inhibitor known for its chemotherapeutic applications. It works by covalently binding with DNA to inhibit synthesis processes, and as an eyedrop, it helps induce apoptosis in myofibroblasts and prevents keratocyte differentiation, playing a crucial role in the management of corneal scarring.
The complexity of treatment regimens, often involving polypharmacy with frequent dosing schedules, exacerbates compliance challenges, particularly among the working-age population where daily responsibilities may impede strict adherence. The introduction of multi agent medications could potentially streamline treatment processes, thereby improving compliance rates. Additionally, the scarcity of accessible written information on ocular chemical burns represents an informational gap that, if filled, could significantly aid in patient and caregiver understanding of the condition and its treatment. Leveraging educational resources and engaging patients' support networks are critical steps toward bolstering treatment adherence.
In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the Corneal Scarring space and more.
Questions Answered
What is the size of clinically and commercially relevant drug-treatable Corneal Scarring populations, and how will drug-treatment rates change over time?
Potential challenges and opportunities in implementing approved therapy for Corneal Scarring.
What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
What key drivers and constraints will affect the Corneal Scarring therapy market over the forecast period?
Report Highlights
Corneal Scarring - Current Market Trends
Corneal Scarring - Current & Forecasted Cases across the G7 Countries
Corneal Scarring - Market Opportunities and Sales Potential for Agents
Corneal Scarring - Patient-based Market Forecast to 2034
Corneal Scarring - Untapped Business Opportunities
Corneal Scarring - Product Positioning Vis-a-vis Competitors' Products
Corneal Scarring - KOLs Insight